170 related articles for article (PubMed ID: 26125761)
1. Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro.
Wang Y; Yin C; Feng L; Wang C; Sheng G
Genet Mol Res; 2015 May; 14(2):5630-41. PubMed ID: 26125761
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of anti-CD47 antibody and Ara-C combination targeting therapy NOD/SCID mouse of myeloid leukemia].
Wang YC; Feng L; Yin CY; Ma LN; Wei YW; Wang CM; Sheng GY
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jul; 15(7):577-82. PubMed ID: 23866283
[TBL] [Abstract][Full Text] [Related]
3. Sorting, identification and enrichment of side population cells in THP-1 acute monocytic leukemia cells.
Wang Y; Yin C; Feng L; Ma L; Wei Y; Sheng G
Oncol Rep; 2013 May; 29(5):1923-31. PubMed ID: 23450319
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia.
Uno S; Kinoshita Y; Azuma Y; Tsunenari T; Yoshimura Y; Iida S; Kikuchi Y; Yamada-Okabe H; Fukushima N
Oncol Rep; 2007 May; 17(5):1189-94. PubMed ID: 17390064
[TBL] [Abstract][Full Text] [Related]
5. CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer.
Yoshida K; Tsujimoto H; Matsumura K; Kinoshita M; Takahata R; Matsumoto Y; Hiraki S; Ono S; Seki S; Yamamoto J; Hase K
Cancer Med; 2015 Sep; 4(9):1322-33. PubMed ID: 26077800
[TBL] [Abstract][Full Text] [Related]
6. Iron Oxide Nanoparticles Combined with Cytosine Arabinoside Show Anti-Leukemia Stem Cell Effects on Acute Myeloid Leukemia by Regulating Reactive Oxygen Species.
Dou J; Li L; Guo M; Mei F; Zheng D; Xu H; Xue R; Bao X; Zhao F; Zhang Y
Int J Nanomedicine; 2021; 16():1231-1244. PubMed ID: 33633448
[TBL] [Abstract][Full Text] [Related]
7. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells.
Piccione EC; Juarez S; Liu J; Tseng S; Ryan CE; Narayanan C; Wang L; Weiskopf K; Majeti R
MAbs; 2015; 7(5):946-56. PubMed ID: 26083076
[TBL] [Abstract][Full Text] [Related]
8. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
[TBL] [Abstract][Full Text] [Related]
9. Soluble extracellular domains of human SIRPα and CD47 expressed in Escherichia coli enhances the phagocytosis of leukemia cells by macrophages in vitro.
Lin Y; Yan XQ; Yang F; Yang XW; Jiang X; Zhao XC; Zhu BK; Liu L; Qin HY; Liang YM; Han H
Protein Expr Purif; 2012 Sep; 85(1):109-16. PubMed ID: 22813925
[TBL] [Abstract][Full Text] [Related]
10. [CD47 and leukemia stem cells].
Cheng QS; Wang XB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1088-91. PubMed ID: 20723335
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.
Zhang M; Hutter G; Kahn SA; Azad TD; Gholamin S; Xu CY; Liu J; Achrol AS; Richard C; Sommerkamp P; Schoen MK; McCracken MN; Majeti R; Weissman I; Mitra SS; Cheshier SH
PLoS One; 2016; 11(4):e0153550. PubMed ID: 27092773
[TBL] [Abstract][Full Text] [Related]
12. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.
Majeti R; Chao MP; Alizadeh AA; Pang WW; Jaiswal S; Gibbs KD; van Rooijen N; Weissman IL
Cell; 2009 Jul; 138(2):286-99. PubMed ID: 19632179
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells.
Kim D; Wang J; Willingham SB; Martin R; Wernig G; Weissman IL
Leukemia; 2012 Dec; 26(12):2538-45. PubMed ID: 22648449
[TBL] [Abstract][Full Text] [Related]
14. [New approaches to target leukemia stem cells].
Takenaka K; Akashi K
Nihon Rinsho; 2014 Jun; 72(6):1018-25. PubMed ID: 25016798
[TBL] [Abstract][Full Text] [Related]
15. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma.
Xiao Z; Chung H; Banan B; Manning PT; Ott KC; Lin S; Capoccia BJ; Subramanian V; Hiebsch RR; Upadhya GA; Mohanakumar T; Frazier WA; Lin Y; Chapman WC
Cancer Lett; 2015 May; 360(2):302-9. PubMed ID: 25721088
[TBL] [Abstract][Full Text] [Related]
16. CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models.
Xu JF; Pan XH; Zhang SJ; Zhao C; Qiu BS; Gu HF; Hong JF; Cao L; Chen Y; Xia B; Bi Q; Wang YP
Oncotarget; 2015 Sep; 6(27):23662-70. PubMed ID: 26093091
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma.
Lo J; Lau EY; So FT; Lu P; Chan VS; Cheung VC; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
Liver Int; 2016 May; 36(5):737-45. PubMed ID: 26351778
[TBL] [Abstract][Full Text] [Related]
18. A new disulfide-linked dimer of a single-chain antibody fragment against human CD47 induces apoptosis in lymphoid malignant cells via the hypoxia inducible factor-1α pathway.
Sagawa M; Shimizu T; Fukushima N; Kinoshita Y; Ohizumi I; Uno S; Kikuchi Y; Ikeda Y; Yamada-Okabe H; Kizaki M
Cancer Sci; 2011 Jun; 102(6):1208-15. PubMed ID: 21401803
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells.
Majeti R
Oncogene; 2011 Mar; 30(9):1009-19. PubMed ID: 21076471
[TBL] [Abstract][Full Text] [Related]
20. A fully human anti-CD47 blocking antibody with therapeutic potential for cancer.
Zeng D; Sun Q; Chen A; Fan J; Yang X; Xu L; Du P; Qiu W; Zhang W; Wang S; Sun Z
Oncotarget; 2016 Dec; 7(50):83040-83050. PubMed ID: 27863402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
